Company
AviadoBio
Revolution in gene therapy for neurodegenerative disorders
- Business model
- B2B
Claim, correct or request removal
Record updated 28 September 2026
About
AviadoBio is a UK-based, clinical-stage gene therapy company focused on developing treatments for neurodegenerative diseases using novel routes of administration. The company is advancing a program to treat an inherited form of frontotemporal dementia, based on pioneering research from King's College London and the UK Dementia Research Institute. Monograph co-led the Series A financing round with NEA in November 2021, and the company entered a partnership with Japanese pharmaceutical group Astellas in 2024.
Loading relationship preview